Table 1 Clinical characteristics of the cohort of patients with NSCLC.
Characteristic | Entire cohort (n = 165) |
---|---|
Age (years) | 66±11.3 |
Sex ratio M/F | 104/50 |
IMC (kg/m2) | 24.5±4.2 |
ASA -n(%) | |
score 1 | 11 (8) |
score 2 | 82 (59) |
score 3 | 44 (32) |
OMS-n(%) | |
score 0 | 40 (29) |
score 1 | 80 (59) |
score 2 | 13 (9.7) |
score 3 | 1 (0.7) |
Type-n(%) | |
Adenocarcinoma | 105 (68) |
Squanmous cell carcinoma | 38 (25) |
Large cell carcinoma | 7 (4.5) |
Carcino-sarcoma | 4 (2.5) |
Stage-n(%) | |
I | 70 (45) |
II | 41 (26) |
III | 43 (28) |
Neoadjuvant chemotherapy-n(%) | 16 (10) |
Adjuvant chemotherapy-n(%) | 59 (38) |
Adjuvant radiotherapy-n(%) | 24 (15) |
Mutations-n(%) | |
TP53 | 64 (41) |
KRAS | 45 (29) |
EGFR | 17 (11) |
STK11 | 8 (5) |
PI3KCA | 6 (4) |
BRAF | 4 (2.5) |
NRAS | 3 (2) |
CTNNB1 | 3 (2) |
SMAD4 | 2 (1) |
FBXW7 | 1 (0.5) |
ERBB2 | 2 (1) |
AKT1 | 2 (1) |
ERBB4 | 3 (2) |
FGFR3 | 1 (0.5) |
PTEN | 2 (2) |
DDR2 | 1 (0.5) |
MAP2K1 | 1 (0.5) |